Chronic hepatitis B and chronic hepatitis C, while caused by different viruses are clinically indistinguishable. Both affect the liver and both are potentially fatal. Over years or decades, chronic HBV and HCV infection can progress to severe liver diseases including cirrhosis, liver cancer, and ultimately end-stage liver failure.
However, until now, few head-to-head comparisons of clinical outcomes have been attempted.
So, we were really interested to read a new study published in the Journal of Clinical Infectious Diseases. This study is the first in which the effects of hepatitis B and hepatitis C virus infections were compared in a relatively homogeneous population.
Approximately 5% of participants entered the study with each type of chronic hepatitis. At the end of an 8 year follow-up, all-cause mortality was similar in both groups, but liver-related mortality was significantly higher for those with chronic hepatitis B infections. This finding held true for both HIV-negative and HIV-positive participants, including those who were severely immune-compromised.
Excluding the few men in the study who underwent treatment for hepatitis C, infection did not change the pattern. However, liver-related deaths among participants who were co-infected with hepatitis B and HIV and who were enrolled after 2002 were markedly lower than among those who were enrolled earlier, possibly reflecting use of newer antiviral drugs that are active against both HIV and hepatitis B virus.
These results are worth noting for a number of reasons. First, they underscore the need for expansion of HBV screening and vaccination to protect against HBV infection. Second, they suggest individuals co-infected with HIV/HBV should be treated with dually active drugs.
And lastly, despite the recent surge of public health advertisements that have brought hepatitis C screening and treatment into the public eye, clinicians should remember that hepatitis B is still out there, and that effective oral treatment can save lives.
Surprised? No conventional molecules, no cholesterol lowering agents, no blood pressure meds and not a single new drug among the top ten. However, they predict the #11 best seller will be GS-7977 – the much anticipated oral hepatitis C drug from Gilead Sciences .
Not so surprising, given the obesity epidemic sweeping the western world that 2 of the front runners are diabetes drugs. Likewise, given the globally aging population – 3 are for arthritis.
#5 may be a surprise to many. Few people had ever heard of myelodysplastic syndrome before ABC news anchor Robin Robertsannounced last week that she has the disease. Still, it’s predicted number 5 status doesn’t mean that an epidemic is expected – it’s still relatively rare with only 10,000 or so new cases detected each year. Its lofty status on the list is more to do with the price. It costs a staggering $10,000 or so for a 28 day supply of the pills.
Other predictions from the EvaluatePharma World Preview 2018 report:
Worldwide prescription drug sales are forecast to total $885bn in 2018 an increase of 3.1% from 2011
Over $290bn of pharmaceutical sales are at risk from patent expirations between now and 2018
Pfizer was the top company for prescription drug sales in 2011, but Novartis will top the list by 2018
Global pharmaceutical R&D spend forecast will grow by 1.5% per year to $149bn in 2018
Anti-coagulants (blood thinners) are set to record highest growth of major therapy categories to 2018
Interesting stuff. But the problem with such long term predictive models is that they are but a snapshot trying to project out six years.
In reality, life is a movie, with a frequently changing plot. For example if J&J’s canagliflozin can reduce obesity and improve blood sugar levels better than Januvia then the projected No. 1 ranking is suspect, at best.